ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
 PMID: 29654894       2018       International journal of antimicrobial agents
Abstract: Despite >50% of M204I/V+-L180M among all HBV resistance cases annually and extensive exposure of patients to lamivudine (LAM), telbivudine (LdT) and adefovir dipivoxil (ADV), ETV resistance also showed a dramatically increased incidence, which rose to 17.1% in 2016.


  Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
 PMID: 29713126       2018       World journal of gastroenterology
Abstract: Eight mutations in RT (rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V, and rtM309K) are significantly associated with HCC progression.
Method: A systematic review by Zhang et al revealed that the global incidence of rt PMID: 29859062       2018       BMC infectious diseases
Abstract: Strong correlation was observed between sP120T and rtM204I/V (P < 0.001), and their co-presence determined an increased HBV-DNA.
Abstract: The immune-associated escape mutations and the NA-induced immune-escape mutations sI195M, sI196S, and sE164D (resulting from drug-resistance mutation rtM204 V, rtM204I, and rtV173L) were retrieved from literature and examined.
Figure: The NA-induced immune-escape mutations


  Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.
 PMID: 30075160       2018       Virus research
Abstract: Sequencing reverse transcriptase region of HBV revealed that the patient developed lamivudine-resistant mutations (rtV173 L, rtL180 M, and rtM204 V) 36 months after the start of lamivudine therapy, and lamivudine-resistant mutants reversed to wild-type after the treatment was stopped for 8 months.


  A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.
 PMID: 30080852       2018       PLoS neglected tropical diseases
Abstract: The commonest RAM was rtM204I/V, either alone or in combination with associated mutations, and identified in both reportedly treatment-naive and treatment-experienced adults.
Abstract: We also identified the suite of mutations rtM204V/I + rtL180M + rtV173L, that has been associated with vaccine escape, in over 1/3 of cohorts.
Result: In addition to South Africa, rtM204I/V was also frequent in Malawi among treatment experienced patients (n = 24/154, 16%) (Fig 3), and in genotype non-A infection: in this setting, the mutation was detected in genotype C infection (n = 2/17, 12%) (S2 Fig).


  Genetic variability in coding regions of the surface antigen and reverse transcriptase domain of hepatitis B virus polymerase, Colombia, 2002-2014
 PMID: 30184362       2018       Biomedica
Abstract: The L180M and M204V resistance mutations were simultaneously identified in one sample, while the I169L resistance mutation was identified in another one.


  Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
 PMID: 30202825       2018       Hepatology communications
Abstract: HBV harboring the rtA181C substitution without LVDr substitutions rtL180M+rtM204V remained susceptible to inhibition by ETV, adefovir, and tenofovir, although cross-resistance to LVD and telbivudine was observed.
Abstract: One LVD-experienced patient-derived HBV RT harboring LVDr substitutions rtL180M+rtM204V with rtA181C displayed reduced ETV susceptibility (122-fold greater than wild-type HBV) and remained susceptible to adefovir and tenofovir.
Discussion: Cross-resistance occurred between ETV and other approved ant


  Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
 PMID: 30586543       2018       The Brazilian journal of infectious diseases
1Abstract: We generated a stable cell line encoding the major pattern of lamivudine-resistant mutations rtL180M/M204V and designated it ""HepG2.RL1""."


  [Monitoring by high-sensitivity HBV DNA assay during treatment in chronic hepatitis B e antigen negative patients].
 PMID: 29804376       2018       Zhonghua gan zang bing za zhi
Abstract: New mutation sites such as G1915A / C, L180M, M204V, V207I / L, T184A and V173L were detected, Low resistance rate (25%).


  The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.
 PMID: 28300730       2017       Antiviral therapy
Abstract: RESULTS: A total of 97 patients in the NA treatment group had resistance mutations, with rtM204I/V/S being the most common substitution (78 of 97), while no resistance mutations were detected in the treatment-naive group.



Browser Board

 Co-occurred Entities




   Filtrator